A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.
Blood Adv
; 2(8): 825-831, 2018 04 24.
Article
in En
| MEDLINE
| ID: mdl-29643105
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myeloid, Acute
/
Neoplasm, Residual
/
High-Throughput Nucleotide Sequencing
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Blood Adv
Year:
2018
Document type:
Article